Fenwick & West LLP represented Omada Health, a San Francisco start-up that makes digital health therapeutic programs for people with type 2 diabetes and other potentially treatable issues, in its recently announced $23 million Series B financing. The round was led by Andreessen Horowitz with participation from Kaiser Permanente Ventures, as well as previous investors U.S. Venture Partners and The Vertical Group. In addition, Balaji Srinivasan of A16Z will be joining the Omada Health board of directors. To date, the company has raised a total of $28.5 million.
With the new funds, the company will take advantage of its position at the nexus between consumer-first apps and enterprise health products. More information on Omada Health can be obtained from the company website.
The Fenwick transaction team was led by corporate partner Michael Esquivel; corporate associates Daniel Parames and Ryan McRobert; and technology transaction partner Stefano Quintini.